Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

HYDROCHLOROTHIAZIDE 50 MG TABLET IS MOST PRESCRIBED GENERIC DOSAGE FORM IN 1984 according to Pharmaceutical Data Services' (PDS) just-released Alpha-Gram for May. Following generic hydrochlorothiazide 50 mg in descending order of total Rxs in 1984, PDS noted, were codeine phosphate/acetaminophen (30 mg tabs), penicillin V potassium (250 mg tabs), tetracycline HCl (250 mg caps), furosemide (40 mg tabs), prednisone (5 mg tabs), and erythromycin stearate (250 mg tabs). Also in the top ten most-prescribed generic dosage forms were penicillin V potassium 500 mg tabs and hydrochlorothiazide 25 mg tabs at eighth and ninth on the PDS list, followed by dypyridamole 25 mg tabs at tenth. "The Top 10 Generics by dosage form were compiled after reviewing over 15 mil. raw Rxs," PDS reported. "This listing was tabulated by similar dosage forms and chemical entity only -- different salts of similar products were calculated independently, as were calculations for tablets, capsules and suspensions which were not combined." PDS also announced that it has put together a marketing research panel of "over 5,000 pharmacies," which is now producing reports that can project new Rx activity to the sales district level. "In addition to one major subscriber," PDS said, "several other pharmaceutical mfrs. are exploring the possibility of using this unique system for district and regional sales analyses, market testing, sales performance evaluation and sales force deployment." The PDS reports measure "the actual dispensing of Rx drugs to consumers," PDS noted, and, consequently, include data on "companies who do not participate in the warehouse withdrawal system."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts